Provided by Tiger Trade Technology Pte. Ltd.

Dyne Therapeutics, Inc.

16.80
+0.25001.51%
Post-market: 16.920.1202+0.72%17:51 EST
Volume:1.42M
Turnover:23.79M
Market Cap:2.72B
PE:-4.64
High:17.49
Open:17.09
Low:16.40
Close:16.55
52wk High:25.00
52wk Low:6.36
Shares:162.00M
Float Shares:152.00M
Volume Ratio:0.72
T/O Rate:0.94%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.6224
EPS(LYR):-3.3716
ROE:-60.66%
ROA:-34.32%
PB:3.93
PE(LYR):-4.98

Loading ...

Company Profile

Company Name:
Dyne Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
2017
Employees:
240
Office Location:
1560 Trapelo Road,Waltham,Massachusetts,United States
Zip Code:
02451
Fax:
781 786 8866
Introduction:
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Directors

Name
Position
Jason Rhodes
Chairman of the Board
John G. Cox
Chief Executive Officer,President and Director
Brian Posner
Independent Director
Vikram Karnani
Independent Director
Carlo Incerti
Director
Catherine Stehman Breen
Director
David Lubner
Director
Dirk Kersten
Director
Edward Hurwitz
Director

Shareholders

Name
Position
John G. Cox
Chief Executive Officer,President and Director
Erick J. Lucera
Chief Financial Officer and Treasurer
Douglas Kerr
Chief Medical Officer
Johanna Friedl Naderer
Chief Commercial Officer
Oxana Beskrovnaya
Chief Scientific Officer